Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Concord Biotech Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹1,008.40Fairly Valued by 0.75%vs CMP ₹1,016.00

P/E (33.5) × ROE (21.4%) × BV (₹174.00) × DY (1.05%)

₹388.80Overvalued by 61.73%vs CMP ₹1,016.00
MoS: -161.3% (Negative)Confidence: 68/100 (Moderate)Models: All 9: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹699.3822%Over (-31.2%)
Graham NumberEarnings₹343.4516%Over (-66.2%)
Earnings PowerEarnings₹242.8513%Over (-76.1%)
DCFCash Flow₹296.6913%Over (-70.8%)
Net Asset ValueAssets₹174.417%Over (-82.8%)
EV/EBITDAEnterprise₹535.959%Over (-47.2%)
Earnings YieldEarnings₹301.307%Over (-70.3%)
ROCE CapitalReturns₹309.929%Over (-69.5%)
Revenue MultipleRevenue₹114.685%Over (-88.7%)
Consensus (9 models)₹388.80100%Overvalued
Key Drivers: EPS CAGR -30.6% drags value — could be higher if earnings stabilize. | Wide model spread (₹115–₹699) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -30.6%

*Investments are subject to market risks

Analyst Summary

Concord Biotech Ltd operates in the Pharmaceuticals segment, NSE: CONCORDBIO | BSE: 543960, current market price is ₹1,016.00, market cap is 10,631 Cr.. At a glance, stock P/E is 33.5, ROE is 21.4 %, ROCE is 28.4 %, book value is 174, dividend yield is 1.05 %. The latest intrinsic value estimate is ₹388.80, around 61.7% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹1,200 Cr versus the prior period change of 18.0%, while latest net profit is about ₹373 Cr with a prior-period change of 22.3%. The 52-week range shown on this page is 2,150/987, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisConcord Biotech Ltd. is a Public Limited Listed company incorporated on 23/11/1984 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L2423…

This summary is generated from the stock page data available for Concord Biotech Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

67
Concord Biotech Ltd scores 67/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health88/100 · Strong
ROCE 28.4% ExcellentROE 21.4% ExcellentD/E 0.05 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money30/100 · Weak
FII holding down -1.77% (6mo) SellingPromoter holding at 44.1% Stable
Earnings Quality55/100 · Moderate
OPM expanding (39% → 42%) ImprovingWorking capital: 193 days Capital intensive
Quarterly Momentum50/100 · Moderate
Revenue (4Q): +6% YoY GrowingProfit (4Q): -4% YoY Declining
Industry Rank90/100 · Strong
P/E 33.5 vs industry 59.5 Cheaper than peersROCE 28.4% vs industry 16.4% Above peersROE 21.4% vs industry 15.2% Above peers3Y sales CAGR: 19% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 26, 2026, 1:18 am

Market Cap 10,631 Cr.
Current Price 1,016
Intrinsic Value₹388.80
High / Low 2,150/987
Stock P/E33.5
Book Value 174
Dividend Yield1.05 %
ROCE28.4 %
ROE21.4 %
Face Value 1.00
PEG Ratio-1.09

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Concord Biotech Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Concord Biotech Ltd 10,631 Cr. 1,016 2,150/98733.5 1741.05 %28.4 %21.4 % 1.00
Sequent Scientific Ltd 8,768 Cr. 201 260/111203 32.20.00 %8.47 %3.21 % 2.00
Marksans Pharma Ltd 8,620 Cr. 190 271/15523.9 59.30.42 %20.0 %16.8 % 1.00
Procter & Gamble Health Ltd 8,530 Cr. 5,139 6,739/4,70029.1 3732.43 %47.8 %36.4 % 10.0
Caplin Point Laboratories Ltd 13,070 Cr. 1,720 2,397/1,50021.3 4160.35 %25.8 %22.7 % 2.00
Industry Average19,737.15 Cr1,103.0859.48201.130.36%16.35%15.16%6.10

All Competitor Stocks of Concord Biotech Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 241273195262241319216310244430204247278
Expenses 129144123143135185135174146239143157176
Operating Profit 1121297211910613481137981906191102
OPM % 46%47%37%45%44%42%38%44%40%44%30%37%37%
Other Income 91278811101015914137
Interest 1111000000000
Depreciation 14141313141413131315181819
Profit before tax 106126651131001317813399185578690
Tax % 26%26%25%25%26%26%25%26%25%23%26%26%25%
Net Profit 799448847597589974142436368
EPS in Rs 7.568.944.638.087.139.295.579.437.0813.574.076.016.48

Last Updated: March 3, 2026, 11:16 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 2:46 am

MetricMar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 2392763404365126177138531,0171,2001,159
Expenses 133145212256308289439509585693714
Operating Profit 105131127180205328274344432507445
OPM % 44%48%37%41%40%53%38%40%42%42%38%
Other Income 118361731142335344443
Interest 10111165310
Depreciation 1010181921285054545469
Profit before tax 106129144178213313241320409496418
Tax % 34%33%30%33%21%25%26%26%26%25%
Net Profit 7087100118169235179238305373315
EPS in Rs 76.3294.78105.66124.48177.65247.44187.7622.7629.1335.6530.13
Dividend Payout % 22%25%0%21%22%0%3%30%30%25%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2015-20162018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)24.29%18.00%43.22%39.05%-23.83%32.96%28.15%22.30%
Change in YoY Net Profit Growth (%)0.00%-6.29%25.22%-4.17%-62.88%56.79%-4.81%-5.86%

Concord Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2015-2016 to 2024-2025.

Growth

Last Updated: September 5, 2025, 3:01 pm

Balance Sheet

Last Updated: March 3, 2026, 12:46 am

MonthMar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 99101010101010101010
Reserves 2683295856737619901,0981,2821,5151,8021,815
Borrowings 3536229528962321032
Other Liabilities 5574697111894144191164219194
Total Liabilities 3674486857639411,1831,3131,5151,6992,0342,021
Fixed Assets 104110189230240546573593575795790
CWIP 197031914118741732115174
Investments 424315122919914274138244335354
Other Assets 202225343285361477592611668854804
Total Assets 3674486857639411,1831,3131,5151,6992,0342,021

Reserves and Borrowings Chart

Cash Flow

MonthMar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 79155167207246265245
Cash from Investing Activity + -42-114-195-112-158-155-160
Cash from Financing Activity + -37-4331-100-85-99-99
Net Cash Flow 0-13-4312-14
Free Cash Flow 79-1-3752101180134
CFO/OP 101%100%74%98%92%85%70%

Free Cash Flow

MonthMar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow70.0095.00105.00171.00153.00239.00212.00312.00422.00504.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 236133131105119117125159
Inventory Days 381310312503434430331286
Days Payable 210112201152185190150135
Cash Conversion Cycle 407331242456368357306310
Working Capital Days 275186159177163153166193
ROCE %27%25%32%21%26%28%28%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 44.08%44.08%44.08%44.08%44.08%44.08%44.08%44.08%44.08%44.08%
FIIs 7.30%7.00%6.49%7.11%8.10%8.33%9.35%9.10%8.03%7.58%
DIIs 8.12%8.40%8.41%10.35%9.89%9.65%9.16%8.85%9.55%9.58%
Public 40.50%40.52%41.03%38.46%37.95%37.93%37.41%37.94%38.32%38.75%
No. of Shareholders 1,00,92787,48683,29680,73784,29882,00481,21982,04582,65081,815

Shareholding Pattern Chart

No. of Shareholders

Concord Biotech Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
DSP Small Cap Fund 1,331,725 0.96 162.55920,4272026-01-25 08:13:2644.69%
SBI Healthcare Opportunities Fund 720,000 2.16 87.88N/AN/AN/A
HSBC Small Cap Fund 591,730 0.47 72.23853,9622025-12-15 03:14:25-30.71%
DSP Healthcare Fund 496,688 2 60.63489,7742026-03-11 07:16:211.41%
Edelweiss Small Cap Fund 280,009 0.62 34.18145,5772026-03-12 02:09:3392.34%
Invesco India Flexi Cap Fund 178,114 0.46 21.74N/AN/AN/A
Nippon India Pharma Fund 111,738 0.16 13.64N/AN/AN/A
LIC MF Flexi Cap Fund 46,609 0.57 5.69N/AN/AN/A
Invesco India Aggressive Hybrid Fund 42,148 0.65 5.14N/AN/AN/A
LIC MF Aggressive Hybrid Fund 23,489 0.55 2.87N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22
FaceValue 1.001.001.0010.00
Basic EPS (Rs.) 35.5229.4522.9516.72
Diluted EPS (Rs.) 35.5229.4522.9516.72
Cash EPS (Rs.) 40.8534.2527.93240.38
Book Value[Excl.RevalReserv]/Share (Rs.) 173.27145.93123.311159.99
Book Value[Incl.RevalReserv]/Share (Rs.) 173.27145.93123.311159.99
Revenue From Operations / Share (Rs.) 114.7197.2181.55749.62
PBDIT / Share (Rs.) 52.6544.4836.19311.96
PBIT / Share (Rs.) 47.4539.3631.02259.33
PBT / Share (Rs.) 47.4039.1130.59253.57
Net Profit / Share (Rs.) 35.6529.1322.76187.76
NP After MI And SOA / Share (Rs.) 35.5229.4522.95183.93
PBDIT Margin (%) 45.8945.7544.3741.61
PBIT Margin (%) 41.3640.4838.0434.59
PBT Margin (%) 41.3140.2337.5133.82
Net Profit Margin (%) 31.0729.9627.9125.04
NP After MI And SOA Margin (%) 30.9630.2928.1424.53
Return on Networth / Equity (%) 20.5020.1818.6115.85
Return on Capital Employeed (%) 26.8226.4124.5421.30
Return On Assets (%) 18.2618.1115.8513.32
Long Term Debt / Equity (X) 0.000.000.000.02
Total Debt / Equity (X) 0.000.000.020.05
Asset Turnover Ratio (%) 0.640.630.600.00
Current Ratio (X) 6.176.303.794.08
Quick Ratio (X) 4.874.842.692.82
Inventory Turnover Ratio (X) 5.360.870.820.00
Dividend Payout Ratio (NP) (%) 24.6323.1922.3140.31
Dividend Payout Ratio (CP) (%) 21.4819.7518.2131.34
Earning Retention Ratio (%) 75.3776.8177.6959.69
Cash Earning Retention Ratio (%) 78.5280.2581.7968.66
Interest Coverage Ratio (X) 1040.58182.3583.9454.11
Interest Coverage Ratio (Post Tax) (X) 705.64120.4153.8033.56
Enterprise Value (Cr.) 17536.5015881.240.000.00
EV / Net Operating Revenue (X) 14.6115.620.000.00
EV / EBITDA (X) 31.8434.130.000.00
MarketCap / Net Operating Revenue (X) 14.6115.660.000.00
Retention Ratios (%) 75.3676.8077.6859.68
Price / BV (X) 9.6710.430.000.00
Price / Net Operating Revenue (X) 14.6115.660.000.00
EarningsYield 0.020.010.000.00

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Concord Biotech Ltd. is a Public Limited Listed company incorporated on 23/11/1984 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ1984PLC007440 and registration number is 007440. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1200.09 Cr. and Equity Capital is Rs. 10.46 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals1482-1486, Trasad Road, Ahmedabad Gujarat 382225Contact not found
Management
NamePosition Held
Mr. Sudhir VaidChairman & Managing Director
Mr. Ankur VaidJoint Managing Director & CEO
Mr. Ravi KapoorNon Executive Director
Mr. Rajiv Ambrish AgarwalNon Executive Director
Mrs. Bharti KhannaIndependent Director
Mr. Amitabh ThakoreIndependent Director
Mr. Arvind AgarwalIndependent Director
Mr. Jayaram EaswaranIndependent Director
Mr. Mandayam Chakravarthy SriramanIndependent Director

FAQ

What is the intrinsic value of Concord Biotech Ltd and is it undervalued?

As of 29 April 2026, Concord Biotech Ltd's intrinsic value is ₹388.80, which is 61.73% lower than the current market price of ₹1,016.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (21.4 %), book value (₹174), dividend yield (1.05 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Concord Biotech Ltd?

Concord Biotech Ltd is trading at ₹1,016.00 as of 29 April 2026, with a FY2026-2027 high of ₹2,150 and low of ₹987. The stock is currently near its 52-week low. Market cap stands at ₹10,631 Cr..

How does Concord Biotech Ltd's P/E ratio compare to its industry?

Concord Biotech Ltd has a P/E ratio of 33.5, which is below the industry average of 59.48. This is broadly in line with or below the industry average.

Is Concord Biotech Ltd financially healthy?

Key indicators for Concord Biotech Ltd: ROCE of 28.4 % indicates efficient capital utilization; ROE of 21.4 % shows strong shareholder returns. Dividend yield is 1.05 %.

Is Concord Biotech Ltd profitable and how is the profit trend?

Concord Biotech Ltd reported a net profit of ₹373 Cr in Mar 2025 on revenue of ₹1,200 Cr. Compared to ₹179 Cr in Mar 2022, the net profit shows an improving trend.

Does Concord Biotech Ltd pay dividends?

Concord Biotech Ltd has a dividend yield of 1.05 % at the current price of ₹1,016.00. The company pays dividends, though the yield is modest.

Last Updated: April 26, 2026, 1:18 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 543960 | NSE: CONCORDBIO
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Concord Biotech Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports